Piramal Pharma Solutions expands API capabilities at Digwal
Piramal Pharma Limited’s (BSE: 500302) Pharma Solutions business, a leading Indian Contract Development and Manufacturing Organization (CDMO), has announced that the company’s site in Digwal in the state of Telangana, India, has implemented various tools to unlock Active Pharmaceutical Ingredient (API) manufacturing capacity and support client needs in drug development and on-patent projects.
Since 2019, Piramal Pharma Solutions (PPS) has made or committed more than $30 million in capital investments, both in the infrastructure and the operational culture at the Digwal site, to improve performance, gain efficiencies, and increase capacity to meet market demands. A driving force of this program is the company’s emphasis on operational excellence (OE) as part of the global corporate culture. By applying specific OE tools such as Theory of Constraint, Value Stream Mapping, Optimization of Unit Operations, and Line Balancing, more than 20% of the site’s capacity has been released to date.
Additional capacity planned
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze